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Abstract
Omics based methods may provide new markers associated to diabetic retinopathy (DR). We 
investigated a wide omics panel of metabolites and lipids related to DR in type 1 diabetes. 
Metabolomic analyses were performed using two-dimensional gas chromatography with time-of-
flight mass spectrometry and lipidomic analyses utilizing an ultra-high-performance liquid 
chromatography quadruple time-of-flight mass spectrometry method in 648 individuals with type 1 
diabetes. Subjects were sub-divided into: no DR, mild non-proliferative DR (NPDR), moderate 
NPDR, severe NPDR and proliferative DR. Endpoints were any progression of DR, onset of DR 
and progression from mild to severe DR tracked from standard ambulatory care and investigated 
using Cox models. The cohort consisted of 648 participants aged mean 54.4±12.8 years, 55.5% 
were male, and follow-up was 5.1-5.5 years. Cross-sectionally, 2,4-dihydroxybutyric acid (DHBA), 
3,4-DHBA, ribonic acid, ribitol, and the triglycerides 50:1 and 50:2 significantly correlated 
(p<0.042) to DR stage. Longitudinally, higher 3,4-DHBA was a risk marker for progression of DR 
(n=133) after adjustment (p=0.033). We demonstrated multiple metabolites being positively 
correlated to higher grade of DR in type 1 diabetes, and several triglycerides being negatively 
correlated. Furthermore, higher 3,4-DHBA was an independent risk marker for progression of DR, 
however, confirmation is required.
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Introduction
One of the most frequent and debilitating complications of diabetes is diabetic retinopathy (DR). 
Despite radical improvements in diagnosis and treatment throughout the last decades (1), DR is still 
the primary cause of blindness in individuals with diabetes aged 20-74 years, and the prevalence  
was 34.6% in a large meta-analysis including 22,896 individuals with diabetes (2). The advances in 
diagnosis and treatment have particularly been made for later stages of the disease and robust and 
specific risk markers for onset and early progression of DR is still lacking. 
Novel omics methods have been developed, allowing for simultaneous evaluation of large panels of 
metabolites using mass-spectrometry-based approaches that allows for comprehensive study of 
metabolic pathways compared to more traditional single-biomarker approaches. Omics facilitates 
advanced and detailed analysis faster than standard methods. More specifically, metabolomics and 
lipidomics is the analysis and categorization of circulating metabolites and lipids using this method; 
and can provide a more comprehensive view of various metabolites’ biological effects (3, 4).
Applying this method to DR is an intriguing concept. Omics allows for a unique ability to 
understand the biological pathways for DR, as well as facilitate the discovery of novel biomarkers 
associated to development and progression.  Few studies have evaluated the association between 
circulating metabolites and presence of DR. In one cross-sectional study, several metabolites were 
associated with DR in type 2 diabetes, amongst them, hydroxyl fatty acids, such as 3,4 
dihydroxybutyric acid and sugar derivatives such as lactose, maltose and ribose (5). Likewise, other 
studies have identified plasma metabolites associated to arginine-, pyrimidine- and fatty acid-related 
pathways, as well as several amino acids highly related to insulin resistance, in relation to DR (6-8). 
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In the present study we investigated the predictive qualities of a wide panel of metabolites and 




Between 2009 and 2011, 648 individuals with T1D and a large range of albuminuria were recruited 
from the outpatient clinic at Steno Diabetes Center Copenhagen. The details of the cohort have 
previously been described (9). Participants were subdivided by stages of albuminuria (normo-, 
micro- and macroalbuminuria). End stage kidney disease, defined as receiving dialysis, renal 
transplantation or glomerular filtration rate (GFR) <15 ml/min/1.73m2 at baseline was an exclusion 
criterium. In the present study, metabomics and lipidomics data along with information on 
retinopathy status was available for 601 (serum metabolomics) and 648 (plasma lipidomics) 
participants, respectively.
The study was conducted in compliance with the Declaration of Helsinki and was approved by the 
local ethics committee. All participants have given informed written consent.
Baseline clinical analyses
Serum creatinine, plasma LDL-cholesterol, triglycerides and HbA1c were measured using 
standardized methods from venous samples. Urinary albumin excretion rate (UAER) was analyzed 
by enzyme immunoassay based on three consecutive 24h urine collections. eGFR was calculated 
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based on serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation. Sitting brachial blood pressure was measured after 10 minutes rest using an 
automated validated device.
Baseline DR stage was classified using in-house algorithms on a 0-4 scale based on regular 
retinopathy screenings at Steno Diabetes Center Copenhagen performed by specifically trained and 
certified nursing staff under supervision of ophthalmologists. Five mydriatic non-stereoscopic 
fundus photos are taken; one macula-centered and four peripheral 45° fundus images. These are 
combined into a mosaic, grading the macula and periphery separately, according to a modified 
version of the International Classification of diabetic retinopathy disease severity scale (10). The 
presence of microaneurysms, intraretinal hemorrhages, hard- or soft exudates and proliferations are 
recorded and quantified. Likewise, intraretinal microvascular abnormalities and venous beading are 
recorded. Based on a weighted quantitation of the distinct retinal pathologies, staging was 
performed. Overall stage was defined as the highest stage diagnosed in either eye. Stage 0 is defined 
as no DR in any eye, stage 1 as mild non-proliferative retinopathy (NPDR), stage 2 as moderate 
NPDR, stage 3 as severe NPDR and stage 4 as proliferative retinopathy (PDR). Blind subjects are 
not screened for retinopathy at Steno Diabetes Center Copenhagen and were therefore excluded. 
Blindness was defined as visual acuity of less than 1/60, lack of ability to count fingers in front of a 
white screen at 1 m distance, and lack of ability to see hand motion in front of a white screen at 1 m 
distance.
Sample quantification and identification
The metabolomics and lipidomics analysis are detailed in Tofte et al. (11) and (12), respectively. 
For completeness, the analyses are outlined here as follows: Serum samples, stored at -80 C, were 
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analyzed by two different analytical methods. Metabolomics samples were analyzed using a two-
dimensional gas chromatography with time-of-flight mass spectrometry. Peak-picking from the raw 
data was performed with ChromaTOF, and the resulting features were aligned with Guineu (13). 
Lipidomics samples were prepared using a modified Folch extraction procedure (14), and analyzed 
by a previously presented ultra high-performance liquid chromatography quadrupole time-of-flight 
mass spectrometry method (UHPLC-Q-TOF-MS) (15). The raw data were pre-processed with 
MZmine 2 (16). A complete list of identified metabolites is available in Tofte et al. (11). Finally, 
the metabolomics and lipidomics data were post-processed in R, as described previously (11, 12). 
Lipid species are defined as number of carbon atoms (indicating total fatty acid chain length) and 
number double-bonds for the specific species. They are presented as “Species(number of carbon 
atoms:number of double-bonds)”.
Within the coverage of the two mass spectrometry platforms, the inclusion of metabolites and lipids 
in subsequent data analysis was solely based on the certainty of identification and the level of 
technical precision, thereby not restricting to any particular pathway or prior hypothesis.
Follow-up
Data regarding retinopathy were obtained using local electronic records from Steno Diabetes Center 
Copenhagen up to December 31st, 2016 and was available for 563 subjects.
The endpoints were defined as 1) progression from any stage to any other stage of DR (any 
progression); 2) onset of DR; and 3) progression from stage 1-2 to stage 3-4 (progression from mild 
to severe DR).
In the case of participants experiencing multiple endpoints, only the first occurrence was included. 
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Statistical analysis
Continuous variables are presented as mean ± standard deviation, if normally distributed and as 
median (interquartile range (IQR)) if skewed. Prior to all analyses, skewed variables were log2 
transformed, including all metabolites, to achieve normal distribution. Categorical variables are 
presented as total number (%). Baseline clinical characteristics were compared across baseline DR 
status using analysis of variance and χ2-test for continuous and categorical variables, respectively.  
Metabolites and lipid species were analysed using a narrowing-down approach in relation to DR 
stages and outcomes as follows: Cross-sectional relationship between single metabolites or lipid 
species and baseline DR stages were assessed using multivariate linear regression models adjusted 
for relevant clinical variables. Thereafter, the single measures were cross-sectionally associated to 
categories of DR stage and tested using ANCOVA. The Benjamini-Hochberg method (pBH) (17, 18) 
was used to correct for multiple testing for presented P-values throughout the analysis. Metabolites 
with pBH<0.05 and lipids with pBH<0.1 in the adjusted cross-sectional model were included in 
survival analysis with the Cox proportional hazards model for onset or progression from mild to 
severe DR of DR. All HRs reported per doubling of metabolite or lipid.
Clinical variables in the adjusted models were age, sex, HbA1c, systolic blood pressure, smoking, 
body mass index, statin treatment, triglycerides, LDL cholesterol and prescribed antihypertensive 
medication.
Partial correlation network analysis was done with the R-package “huge” (19) using the graphical 
LASSO algorithm (20) coupled with the extended Bayesian information criterion (21). All 
metabolites were included in inferring the network. Subsequently, the subnetwork of metabolites, 
which were immediately connected to the four retinopathy-associated metabolites, were visualized 
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with the R-package qgraph (22). Edges or the network were colored by the respective partial 
correlation in the graphical LASSO model, and nodes were colored with respective Spearman 
correlation to the top candidate biomarkers. In both color annotations, red and blue refer to positive 
and negative correlation, respectively. Size of nodes refers to the respective degree (i.e., the number 
of associations to other nodes). Statistical analysis and data visualization were performed using R 
(version 3.4.2)
Data and resource availability
The data sets generated during and/or analyzed during the current study are available from the
corresponding authors on reasonable request.
Results
Baseline characteristics
Baseline characteristics for the participants divided according to baseline DR stages is shown in 
Table 1. The majority had no DR (n=141, 22%) or moderate NPDR (n=186, 29%). When 
comparing to no DR, participants with PDR had higher mean (SD) BMI (24.7 (3.5) versus 26.8 
(11.2) kg/m2), UAER (11.5 (IQR: 7.6-22.4) versus 49.0 (IQR: 14.9-231.8) mg/24h) and systolic 
blood pressure (127 (46.1) versus 135 (20.3) mmHg), and lower eGFR (94.8 (24.7) versus 64.5 
(30.6) ml/min/1.73 m2). Across groups age, systolic blood pressure and UAER was higher with 
higher DR stage, and the eGFR was lower. Also, the frequency of treatment with antihypertensive 
drugs and statins was higher with higher DR stage.
Page 8 of 33Diabetes
9
Metabolomic cross-sectional analyses
A total of 75 metabolite species were identified and passed quality control (Supplementary Table 
1). These metabolites were included in the multivariate linear regression models. Four metabolites 
were positively correlated to baseline DR stage after adjustment for clinical variables and correction 
for multiple testing: 2,4-dihydroxybutyric acid (2,4-DHBA; pBH<0.001), ribonic acid (pBH=0.017), 
ribitol (pBH=0.032) and 3,4-DHBA (pBH=0.036). Thereafter, all 75 metabolites were included in 
ANCOVA for baseline DR stages: the same four metabolite levels were significantly increased by 
higher DR stage after adjustment (ribonic acid, pBH<0.001; 2,4-DHBA, pBH<0.001; ribitol, 
pBH=0.013 and 3,4-DHBA pBH=0.041 - Table 2). Figure 1 illustrates the distribution and relative 
levels of these four metabolites. It is apparent that the levels of all four metabolites increase with 
higher DR stage. Both, 2,4-DHBA and 3,4-DHBA (Figure 1 B and D), follow the same pattern of 
lower levels of the metabolite for no DR and NPDR, and a non-linear increase towards higher DR 
stages and PDR, in particular. In contrast, the levels of ribonic acid and ribitol (Figure1 A and C) 
increase linearly with increasing DR stage. 
The partial correlation network of the metabolome connected to the four metabolites is shown in 
Figure 2. This network included kidney function-related metabolites (such as creatinine and myo-
inositol), glucose metabolism-related compounds (such as citric acid and glycine), fatty acids (such 
as fumaric acid and malic acid) and amino acids (such as alanine and serine). Particularly creatinine 
and myo-inositol, but also glyceryl-glycoside, 4-hydroxybenzeneacetic acid and fumaric acid, were 
highly associated with the hub of the four retinopathy-associated metabolites. Except for the amino 
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acids, most of the compounds in the network were positively correlated with the four highlighted 
metabolites, as indicated by red color in Figure 2.
Lipidomic cross-sectional analyses
After identification and quality control, a total of 104 lipid species from the following five major 
lipid classes were included in the analyses:  diacyl-phosphatidylcholines (PCs), alkyl-acyl-
phosphatidylcholines (PC-Os), lyso-phosphatidylcholines (LPCs), triacylglycerols (TGs) and 
sphingomyelins (SMs). Lipid species are defined as number of carbon atoms (indicating total fatty 
acid chain length) and number double-bonds for the specific species. They are presented as 
“Species(number of carbon atoms:number of double-bonds)”. The investigated lipids are listed in 
Supplementary Table 2.  
Two triacylglycerols TG(50:1) and TG(50:2) were inversely associated with DR grade at baseline 
after adjustment for clinical covariates, when testing with linear regression analysis (pBH<0.05). 
Furthermore, LPC(16:1), PC(32:1), TG(14:0/16:0/18:1), TG(50:3) and PC(32:2) were inversely 
associated with baseline DR grade at a higher false discovery rate of 10 %. 
When investigating with ANOVA, a difference in the lipid level between the DR grades was 
detected in lyso-phosphatidylcholine LPC(16:0) (pBH<0.1). This association was lost after 
adjustment for the clinical covariates (ANCOVA). In addition to LPC(16:0), medium-sized 
unsaturated TGs and small LPCs had stronger indicative associations with DR grade than other 
lipids, as shown in the lipidome-wide heatmap of the ANCOVA F-statistics (Figure 3). In 
particular, LPCs(16:1) as well as TGs 49:3, 50:1 and 50:2 emerged with an indicative association 
with the DR grade.
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Longitudinal analyses
Metabolites and lipids identified in cross-sectional analyses were thereafter analyzed with 
compound-specific Cox proportional hazards models for association to any progression, onset of 
DR, and progression from mild to severe DR. Median follow-up ranged between 5.1-5.5 years 
depending on endpoint. The number of events were 133, 47, and 29 for any progression, onset of 
DR and progression from mild to severe DR respectively. For the any progression endpoint, higher 
3,4-DHBA exhibited significance after adjustment for clinical covariates and multiple testing (HR 
(CI 95%):1.55 (1.12-2.15), p=0.033). The other metabolites were not associated with any of the 
endpoints neither before nor after adjustment. Although not statistically significant, 2,4-DHBA 
showed a high HR for progression from mild to severe DR (HR (CI 95%): 1.92 (0.94-3.93), 
p=0.290). Unadjusted and adjusted HRs for the metabolites are presented as a forest plot in Figure 
4. 
Unlike the metabolites, none of the lipids were independent risk factors for any of the endpoints 
(p>0.05).
Discussion
The present study illustrates an exciting new avenue in characterizing T1D individuals with DR. In 
the present cohort we have investigated individuals with long diabetes duration and a broad range of 
albuminuria, leading to a high proportion of subjects with more severe DR than would be expected 
in a general clinical population with T1D. We identified four metabolites associated with presence 
of DR, as well as higher 3,4-DHBA as an independent risk marker for progression of DR. Our 
Page 11 of 33 Diabetes
12
results were independent of a panel of metabolic risk factors traditionally used for risk stratification 
of DR in T1D. Therefore, we now argue for the need for further investigation of omics-based risk 
stratification of DR. Using omics in relation to DR is a relatively new venture and clinical studies 
assessing its viability are sparse, especially in subpopulations such as individuals with T1D, and 
using longitudinal data. 
The metabolites identified in this study mainly stem from two etiopathogenic factors, namely 
hyperglycemia (ribitol and ribonic acid) and dyslipidemia (2,4- and 3,4-DHBA) (23). Ribitol and 
ribonic acid are derivatives from ribose which is highly active in the pentose phosphate pathway, in 
the production of nucleotides and nucleic acids. Furthermore, sugar alcohols such as sorbitol, are 
active in the polyol pathway which has been identified as a crucial insulin-independent pathway 
relevant in the onset of DR, and have been suggested as a possible therapeutic target in the 
treatment of DR (24). The fructose created in this pathway becomes further phosphorylated 
resulting in the formation of advanced glycation end products (AGEs) which in turn bind to 
receptors for AGEs (RAGE) - a known facilitator of DR (25). 
DHBAs on the other hand, which are closely related to the ketone body hydroxybutyric acid, have 
not been directly associated with any major pathways implicated in the onset of DR or T1D. Other 
diseases, such as succinic semialdehyde dehydrogenase deficiency, an autosomal recessive genetic 
disease, leads to 4-DHBA aggregation, and, in turn, is associated to severe neurological 
complications and symptoms (26). In general, ketone bodies are associated with dyslipidemia and 
high fat diets (27), which are highly relevant risk factors in the development of diabetic 
complications. A theory that has drawn recent attention is that DHBAs could be implicated in the 
butyrate metabolism by the gut microbiota (28), although at present this still calls for more 
investigation. Similarly, Sumarriva et al. (6) demonstrated that higher  plasma carnitine, a 
metabolite highly present in meat-containing food, was associated to the presence of PDR compared 
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to NPDR. Carnitine is further metabolized by the gut microbiota, into trimethylamine-N-oxide that 
has been associated to cardiovascular and metabolic diseases (29).
Interestingly, visualized in Figure 2, the sub-network of metabolites associated with DR, show that 
all metabolites which correlated significantly with DR in this study, all seem strongly associated to 
myo-inositol. Despite myo-inositol itself not being associated to DR, in this study, the association to 
the other metabolites could propose another pathway of DR etiology. Myo-inositol is a sugar 
alcohol which gastrointestinal absorption and intracellular transport has been shown to be impaired 
in individuals with diabetes (during hyperglycemia) (33). Furthermore, while previously thought 
mainly to be expressed in renal tissue, recent studies show evidence of myo-inositol activity in 
extra-renal tissue such as retinal and lens epithelium as well (34, 35), and has additionally been 
associated to existing DR in individuals with type 2 diabetes (36).
Our metabolomic results stand well in relation to a study by Chen et al., describing similar 
metabolites associated to DR in a cross-sectional study including type 2 diabetes individuals with 
DR (n=40) or without DR (n=40) in the Singaporean Indian Eye Study. They demonstrated that 3,4-
DHBA as well as ribose were significantly higher in the DR group compared to the one without. 
Furthermore, similar results were found for 2-deoxyribonic acid as well as for several other sugars 
and sugar derivates (5). As such, we can partly validate these results in our larger population of 
T1D individuals, and additionally, we have shown that 3,4 DHBA was a risk marker for 
progression of DR during follow up. The inherent issue with omics discovery studies being 
explorative, is that replication of results is necessary across populations and cohorts, but often 
difficult, especially due to platform heterogeneity. The study by Chen et al. strengthens the findings 
in our study suggesting that 3,4 DHBA and ribose derivatives are valid risk markers of DR. 
However, Lin et al. showed that branched-chain, aromatic and glucogenic amino acids such as 
leucine, valine, tyrosine and alanine was positively associated with diabetic microangiopathy in 
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type 2 diabetes. These amino acids were also investigated in our study; however, we could not 
confirm the results, possibly due to the heterogeneity between type 1 and type 2 diabetes.
In the case of lipids, some, such as LDL cholesterol and TGs, have throughout many years been 
comprehensively studied and have proved to be robust risk markers for vascular disease in T1D. In 
addition, studies targeting dyslipidemia with fibrates have found beneficial effects on retinopathy 
(37, 38). Therefore, the concept of applying lipidomic strategies into finding novel markers to 
strengthen the identification and prediction of vascular risk, are not implausible. In our panel of 
lipids, we were only able to identify three TGs negatively correlated with DR stage in our linear 
models using a 5% α-level, adjusted for i.a. baseline LDL-cholesterol, triglycerides and body mass 
index. However, these associations could not be replicated in ANCOVA models, arguably in part 
due to non-linear trends for different lipids across DR stages.
It is difficult to compare the present results in relation to other studies as very few have investigated 
DR. One study found stearic acid, trans-oleic acid, linoleic acid, arachidonic acid and free 
cholesterol in circulation to be significant differentiators between preclinical DR, NPDR and PDR 
(39). Likewise, Schwartzman et al. identified several free-fatty acid autacoids in vitreous humor as 
markers of PDR in T1D (40). 
Proliferative DR is demonstrated to be associated to an impaired blood-brain barrier (BBB), and  
early damage to the BBB is hypothesized to be a predictor of progression to more advanced stages 
of DR (41). However, the mechanisms for the association surrounding BBB impairment and DR are 
not understood, and the association to circulating biomarkers has not been described. Hogan et al. 
demonstrated that various polyunsaturated fatty acids and sphingolipids was associated with 
impaired BBB in traumatic brain injury in rats (42), but our results do not support the association 
between these and DR. 
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Moving outside of purely metabolomic and lipidomic studies, a substantial amount of research has 
been performed on the  proteome and its effect on DR risk and risk progression, however primarily 
in small samples with largely non-replicated results (43). 
This study is not without limitations. The DR staging during follow up did not take laser surgery or 
VEGF injections into account, as it was based only on changes in DR stage from baseline. 
Furthermore, no data on concomitant medication throughout the follow-up was available, and as 
such there is no data on how statins or antihypertensive medication, or insulin treatment have 
changed during follow up. In addition, no information on lifestyle parameters, which could have 
influence on lipid composition, were available at baseline. Finally, the lack of a validation 
population is another limiting factor. Nonetheless, the sizable strengths of this study are firstly the 
large, well-defined cohort of individuals with T1D, including 7 years of longitudinal data, and 
secondly a comprehensive metabolomic and lipidomic analysis regarding presence of and changes 
in DR in T1D.
In summary, we identified four metabolites and three lipids with an association to the DR stage: 
ribonic acid, ribitol, two dihydroxybutyric acids were associated with DR stage and three 
triglycerides were negatively correlated with the DR stage. Furthermore, we have identified the 3,4-
dihydroxybutyric acid as an independent risk marker for progression in DR stage. Our results may 
serve as a basis for further studies regarding sugar metabolism, hydroxy acids and lipids in relation 
to diabetic complications such as retinopathy, as more investigative studies are needed before these 
markers can be clinically applied.
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Tables
Table 1: Baseline characteristics across diabetic retinopathy stage. 
Data are mean (standard deviation) or median (inter-quartile range), HbA1c: Glycated hemoglobin, eGFR: Estimated glomerular filtration rate, UAER: Urinary albumin 
excretion rate, SBP: Systolic blood pressure, DR: Diabetic retinopathy, NPDR: Non-proliferative diabetic retinopathy, PDR: Proliferative diabetic retinopathy. P-
values was calculated using analysis of variance and χ2-test for continuous and categorical variables, respectively.




Severe NPDR PDR p
n (%) 141 (21.8) 90 (14.0) 186 (28.8) 121 (18.8) 107 (16.6) -
Men, n (%) 69 (49.3) 47 (52.2) 120 (64.5) 62 (51.7) 60 (56.1) 0.051
Age, years 46.5 (15.1) 54.9 (11.8) 56.4 (10.7) 59.1 (10.8) 55.8 (10.9) <0.001
Diabetes duration, years 16.8 (15.5) 32.1 (16.1) 33.1 (12.4) 41.4 (10.8) 41.3 (9.0) <0.001
Smokers, n (%) 29 (20.6) 17 (18.9) 46 (24.7) 20 (16.5) 21 (19.6) 0.495
BMI, kg/m2 24.7 (3.5) 24.3 (3.7) 25.8 (4.3) 25.8 (3.8) 26.8 (11.2) 0.014
HbA1c, mmol/mol 64.3 (14.7) 61.7 (11.2) 63.9 (11.3) 66.0 (13.8) 65.5 (11.4) 0.130
HbA1c, % 8.0 (1.3) 7.8 (1.0) 8.0 (1.0) 8.2 (1.3) 8.1 (1.1) 0.130
eGFR, ml/min/1.73m2 95 (25) 91 (23) 89 (24) 75 (27) 64 (31) <0.001
UAER, mg/24h 12 (8-22) 9 (6-24) 15 (8-53) 29 (9-122) 49 (15-232) <0.001
SBP, mmHg 127 (16) 129 (15) 132 (16) 134 (18) 135 (20) 0.001
Antihypertensive treatment, n (%) 58 (41.4) 49 (54.4) 138 (74.2) 109 (90.1) 103 (96.3) <0.001
Total cholesterol, mmol/l 4.7 (0.8) 4.7 (0.8) 4.7 (0.9) 4.7 (0.9) 4.6 (0.9) 0.673
Triglycerides, mmol/l 0.9 (0.7-1.3) 0.9 (0.7-1.1) 1.0 (0.8-1.4) 0.9 (0.7-1.3) 1.0 (0.7-1.5) 0.055
Statin treatment, n (%) 54 (38.6) 44 (48.9) 113 (60.8) 92 (76.0) 81 (75.7) <0.001
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Table 2: Cross-sectional association between metabolites and lipids and baseline diabetic retinopathy (DR) 
grade.
Association to DR grade 
(MLR) Effect CI (95%) p pBH
Metabolites
2,4-DHBA 0.097 0.058;0.135 <0.001 <0.001
Ribonic acid 0.109 0.049;0.170 <0.001 0.017
Ribitol 0.072 0.028;0.116 0.001 0.032
3,4-DHBA 0.059 0.022;0.097 0.002 0.036
Lipids
TG(50:2) -0.066 -0.104;-0.028 <0.001 0.042
TG(50:1) -0.074 -0.118;-0.030 0.001 0.042
PC(32:2) -0.085 -0.140;-0.029 0.003 0.083
LPC(16:1) -0.087 -0.146;-0.028 0.004 0.084
TG(14:0/16:0/18:1) -0.065 -0.109;-0.021 0.004 0.084
TG(50:3) -0.053 -0.091;-0.016 0.006 0.092
PC(32:1) -0.080 -0.137;-0.023 0.006 0.092
Association to DR grade
(ANCOVA) F p pBH
Metabolites
Ribonic acid 7.44 <0.001 <0.001
2,4-DHBA 6.58 <0.001 0.001
Ribitol 4.98 <0.001 0.013
3,4-DHBA 4.18 <0.001 0.041
Lipids
TG(50:1) 3.97 0.003 0.223
TG(50:2) 3.55 0.007 0.257
TG(49:3) 3.44 0.009 0.257
LPC(16:1) 3.12 0.015 0.354
LPC(16:0) 2.71 0.030 0.544
TG(52:2) 2.62 0.034 0.544
TG(14:0/16:0/18:1) 2.58 0.036 0.544
PC(32:1) 2.44 0.046 0.547
TG(16:0/18:0/18:1) 2.37 0.052 0.547
PC(32:2) 2.29 0.059 0.547
Table 2: Presented in the top half are multivariate linear regression model effect sizes per increase in DR grade, for each 
metabolite or lipid to baseline DR grade with 95% CI and crude and Benjamini-Hochberg adjusted p-values. In the 
bottom half of the table are ANCOVA F-values presented for each metabolite and lipid to baseline DR grade with crude 
and adjusted p-values. All presented models include the following baseline covariates: age, sex, glycated hemoglobin, 
systolic blood pressure, smoking, body mass index, statin treatment, triglycerides, low-density lipoprotein cholesterol, 
and prescribed antihypertensive medication. MLR: Multivariable linear regression, pBH: Benjamini-Hochberg adjusted 
p-value, DHBA: Dihydroxybutyric acid, TG: Triacylglycerol, LPC: Lyso-phosphatidylcholine, PC: Diacyl-
phosphatidylcholine




Violin plots showing metabolite levels across baseline diabetic retinopathy stages. Shown are four 
metabolites, where a difference between the stages was detected using ANCOVA. Observations are 
shown as dots and their distribution in each of the stages of retinopathy as a violin geom. Pairwise 
differences between the stages are indicated with p-values at the top-part of the figure. The results 
are from models with adjustment for age, sex, HbA1c, systolic blood pressure, smoking, BMI, statin 
treatment, triglycerides, LDL cholesterol and prescribed antihypertensive medication. A: ribonic 
acid, B: 2,4-dihydroxybutyric acid, C: ribitol, and D: 3,4-dihydroxybutyric acid, HbA1c: glycated 
hemoglobin, DR: Diabetic retinopathy, NPDR: Non-proliferative DR, PDR: Proliferative DR
Figure 2:
Partial correlation network showing associations in the measured metabolome. Metabolites with 
cross-sectional association to retinopathy (ribitol, ribonic acid, 2,4-dihydroxybutyric acid and 3,4-
dihydroxybutyric acid) are indicated as diamonds-shaped nodes. The node color of the other 
metabolites (circlular nodes) indicates the Spearman correlation to ribonic acid. Partial correlations 
(i.e., independent associations) are indicated by lines between the metabolites, where thickness and 
color of the line, respectively, indicate the strength and the sign of the association (red: positive, 
blue: inverse). Additionally, size of the node indicates the degree of the node (i.e., the number of 
associations with the metabolite).
Figure 3:
Heatmaps of the ANCOVA model F-statistics across the entire lipidomic panel in relation to 
diabetic retinopathy stage. The results are from models with adjustment for age, sex, HbA1c, 
systolic blood pressure, smoking, body mass index, statin treatment, triglycerides, LDL cholesterol 
and prescribed antihypertensive medication. Lipid species are grouped according to the lipid classes 
in each panel. Each cell represents one lipid species. On the y-axis is number of double-bonds for 
the specific species (indicating level of saturation) and on the x-axis is the number of carbon atoms 
(indicating total fatty acid chain length).
Figure 4:
Forest plot of multiple-testing-corrected hazard ratios of the selected metabolites for three 
retinopathy events: any retinopathy, onset of retinopathy, and progression from mild to severe 
retinopathy(top, middle and bottom panels, respectively). Adjusted model (right) is adjusted for age, 
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sex, HbA1c, systolic blood pressure, smoking, BMI, statin treatment, triglycerides, LDL cholesterol 
and prescribed antihypertensive medication. Crude model (left) is without these adjustments.
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Violin plots showing metabolite levels across baseline diabetic retinopathy stages. Shown are four 
metabolites, where a difference between the stages was detected using ANCOVA. Observations are shown as 
dots and their distribution in each of the stages of retinopathy as a violin geom. Pairwise differences 
between the stages are indicated with p-values at the top-part of the figure. The results are from models 
with adjustment for age, sex, HbA1c, systolic blood pressure, smoking, BMI, statin treatment, triglycerides, 
LDL cholesterol and prescribed antihypertensive medication. A: ribonic acid, B: 2,4-dihydroxybutyric acid, C: 
ribitol, and D: 3,4-dihydroxybutyric acid, HbA1c: glycated hemoglobin, DR: Diabetic retinopathy, NPDR: 
Non-proliferative DR, PDR: Proliferative DR 
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Figure 2: 
Partial correlation network showing associations in the measured metabolome. Metabolites with cross-
sectional association to retinopathy (ribitol, ribonic acid, 2,4-dihydroxybutyric acid and 3,4-dihydroxybutyric 
acid) are indicated as diamonds-shaped nodes. The node color of the other metabolites (circlular nodes) 
indicates the Spearman correlation to ribonic acid. Partial correlations (i.e., independent associations) are 
indicated by lines between the metabolites, where thickness and color of the line, respectively, indicate the 
strength and the sign of the association (red: positive, blue: inverse). Additionally, size of the node indicates 
the degree of the node (i.e., the number of associations with the metabolite). 
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Figure 3: Heatmaps of the ANCOVA model F-statistics across the entire lipidomic panel in relation to diabetic 
retinopathy stage. The results are from models with adjustment for age, sex, HbA1c, systolic blood 
pressure, smoking, body mass index, statin treatment, triglycerides, LDL cholesterol and prescribed 
antihypertensive medication. Lipid species are grouped according to the lipid classes in each panel. Each cell 
represents one lipid species. On the y-axis is number of double-bonds for the specific species (indicating 
level of saturation) and on the x-axis is the number of carbon atoms (indicating total fatty acid chain 
length). 
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Figure 4: Forest plot of multiple-testing-corrected hazard ratios of the selected metabolites for three 
retinopathy events: any retinopathy, onset of retinopathy, and progression from mild to severe retinopathy 
(top, middle and bottom panels, respectively). Adjusted model (right) is adjusted for age, sex, HbA1c, 
systolic blood pressure, smoking, BMI, statin treatment, triglycerides, LDL cholesterol and prescribed 
antihypertensive medication. Crude model (left) is without these adjustments. 
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Supplementary Table 1: Metabolites















































































Supplementary Table 2: Lipids
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